Aurinia Pharmaceuticals Inc. (AUPH): Total Liabilities
$170.26M
As of 2025-12-31
$177.40M
As of 2026-06-30
+37.5%
3-year compound annual growth
+24.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $170.26M | -1.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $173.17M | +1.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $170.11M | +160.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $65.42M | +1.8% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $64.28M | +15.0% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $55.91M | +117.5% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $25.70M | n/a | 2021-02-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $170.26M | -1.7% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $92.32M | +97.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $262.35M | -13.0% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $130.21M | +65.8% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $62.55M | -31.0% |
Compare AUPH, SMMT, KNSA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗